NCT05212701 2024-04-30To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerDompé Farmaceutici S.p.APhase 2 Withdrawn
NCT01861054 2021-05-14Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast CancerDompé Farmaceutici S.p.APhase 2 Terminated20 enrolled 16 charts